The Modesto Bee Local Stock Index
Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
JAZZ PHARMACEUTICAL (NQ: JAZZ)
69.66 USD  +0.16 (+0.23%)
Official Closing Price  /  Updated: 4:00 PM EDT, Jun 18, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about JAZZ PHARMACEUTICAL
 
New Research Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis
June 13, 2013
from PR Newswire
New Research at SLEEP 2013 Demonstrates People with Narcolepsy Face Significant Health and Economic Burden and High Rates of Misdiagnosis
June 05, 2013
First U.S. study to highlight severe comorbidities and economic burden associated with narcolepsy Read More
from PR Newswire
Jazz Pharmaceuticals Announces Participation In Upcoming Investor Events
May 13, 2013
from PR Newswire
JAZZ PHARMACEUTICALS ANNOUNCES FIRST QUARTER 2013 FINANCIAL RESULTS
May 07, 2013
Company Reports Total Revenues of $196 Million Driven by Record Net Sales of Xyrem and Erwinaze Read More
from PR Newswire
Jazz Pharmaceuticals To Report First Quarter 2013 Financial Results On May 7, 2013
April 23, 2013
from PR Newswire
Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
March 05, 2013
from PR Newswire
Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
March 04, 2013
from PR Newswire
Jazz Pharmaceuticals Announces Participation At Two Investor Conferences In March
February 27, 2013
from PR Newswire
Jazz Pharmaceuticals plc and Concert Pharmaceuticals Announce Worldwide Licensing Agreement to Develop and Commercialize Deuterium-Modified Sodium Oxybate
February 26, 2013
from Business Wire News Releases
Jazz Pharmaceuticals Reports Full Year And Fourth Quarter 2012 Financial Results
February 26, 2013
- Record Total Revenues of $586 Million in 2012 - Read More
from PR Newswire
Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
February 11, 2013
from PR Newswire
Free Research Report on Jazz Pharmaceuticals, Inc., Furiex Pharmaceuticals, Inc., Sunesis Pharmaceuticals, Inc., Prestige Brands Holdings, Inc. and Synta Pharmaceuticals, Inc.
January 30, 2013
from PR Newswire
The Reason It Trades, What's Moving CS, JAZZ, WNC and ALE
January 30, 2013
from Marketwired News Releases
Where Opportunity is Found - Research Report on Jazz Pharmaceuticals plc and Spectrum Pharmaceuticals, Inc.
January 23, 2013
As industry marked by roller coaster ups and downs, where does opportunity lie ahead? Which companies have what it takes to survive regulatory approval and oversight? Read More
from PR Newswire
The Real Story Behind LEE, CMVT, JAZZ and RENN
January 23, 2013
from Marketwired News Releases
Key to Success, How to Profit: CLSN, GALE, KERX and JAZZ
January 11, 2013
from Marketwired News Releases
Perfect Trade Setups, How to Play CLSN, GALE, KERX and JAZZ
January 09, 2013
from Marketwired News Releases
Jazz Pharmaceuticals to Webcast Presentation at J.P. Morgan Healthcare Conference
January 02, 2013
from PR Newswire
Jazz Pharmaceuticals Announces Presentation Of Largest Safety Trial To Date Of Patients Treated With Erwinaze®
December 10, 2012
-- Data from Compassionate Use Protocol Presented at the 2012 American Society of Hematology Annual Meeting -- Read More
from PR Newswire
Key to Success, How to Profit: GALE, KERX and JAZZ
December 06, 2012
from Marketwired News Releases
The Real Story Behind GALE, KERX and JAZZ
December 05, 2012
from Marketwired News Releases
Jazz Pharmaceuticals Announces Issuance of Additional Xyrem® Patent
December 04, 2012
from PR Newswire
Jazz Pharmaceuticals Begins Clinical Trial of Intravenously Administered Erwinaze® In Patients with Acute Lymphoblastic Leukemia
December 03, 2012
from PR Newswire
Jazz Pharmaceuticals Announces Participation In Three Investor Conferences In November
November 09, 2012
from PR Newswire
Jazz Pharmaceuticals Announces Third Quarter 2012 Results
November 08, 2012
-- Company Reports Revenues of $176 Million, Excluding $8 Million from the Women's Health Discontinued Operations -- Read More
from PR Newswire
Jazz Pharmaceuticals Announces Support for National Campaign Designed to Curb Prescription Drug Abuse
November 05, 2012
- Company Helps Fund The Medicine Abuse Project - Read More
from PR Newswire
Jazz Pharmaceuticals Announces Date to Release Third Quarter 2012 Results
October 29, 2012
from PR Newswire
Jazz Pharmaceuticals Completes Sale of its Women's Health Business to Meda
October 15, 2012
from PR Newswire
Critical Alerts For Yahoo!, Adobe, Pulte Homes, Jazz Pharmaceuticals, and Tyson Foods Released By InvestorsObserver
September 19, 2012
from PR Newswire
/C O R R E C T I O N -- Jazz Pharmaceuticals/
September 12, 2012
from PR Newswire
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here